American Healthcare REIT stock
AHRNYSEAmerican Healthcare REIT, Inc., Real EstateISIN US3981823038
55Score 55 out of 100, Neutral
Price and trend
81 / 100
Price history
+22% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Overheated: the price has risen very quickly lately (RSI 72).
The price is 1.3% below its 52-week high. Largest decline in 3 years: 14% (July 2026 to October 2026).
Chart figures for advanced users
- SMA 50$53.35
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$51.93
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)72
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$45.69
- The lowest closing price of the last twelve months.
- Resistance$59.39
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- American Healthcare REIT, Inc. belongs to the REIT (Healthcare Facilities) industry (United States) and, with a market value of $13.61B, is number 5 of 18 companies in its industry on MEQIRI.
- MEQIRI Score 55 out of 100 (Neutral): rank 157 of 325 in Real Estate, median 55.
- The P/E is 132.6 (REIT (Healthcare Facilities) median 14.5, own median of recent years 112).
Show more
- For real estate investment trusts (REITs) what counts is funds from operations (FFO and AFFO). The P/E and the payout ratio of earnings say little here, because depreciation on properties depresses earnings.
- Our model puts fair value at $35.75, with the price 64% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 66.6% a year since 2020.Growth 90
- Earnings turn into cashFree cash flow 209% of earnings over the last 12 months.Fundamentals 51
- Analysts expect strong earnings growthUp 24.8% a year through 2028 (estimates from 4 analysts).Growth 90
Weaknesses
- DilutionShare count up 151% since 2020.Capital allocation 23
- Richly valuedP/E 132.6, REIT (Healthcare Facilities) median 14.5, own median 112.Valuation 17
- Above fair valuePrice 64% above the fair value of $35.75.Valuation 17
Its standout strengths are growth and technical analysis, while capital allocation and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 56 to 55.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
- weak fundamentals
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $27.50 and expensive above $51.07 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $41.66 (cash-flow model) and $29.84 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $32.18, at 7.8% it would be $41.10.
Valuation metrics
Half from the cash-flow model, half from FFO per share times the median price to FFO of the REIT industry (16.6). For REITs, depreciation on buildings depresses earnings, so FFO counts instead of earnings, here following the industry rule (Nareit) from the filings with the SEC: gains on property sales are deducted where the company reports them in the standard items. The cash-flow model uses AFFO: operating cash flow less maintenance, estimated at 4% of revenue, and less preferred dividends. New construction and acquisitions do not count as running costs there.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 21.5% on the twelve months before. Revenue has grown solidly since 2016, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 21%, operating 7%, net 3%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported $0.14 (expected $0.15)below expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 7.3% since 15 Oct 2026.
- Earnings per share
- $0.61+2.5%
- Revenue
- $2.81B+0.3%
- Earnings per share
- $0.84+7.3%
- Revenue
- $3.19B+1.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +1.4%2026 guidance raised: NFFO per share of $2.15 to $2.19 from $2.03 to $2.09, and same-store NOI growth of 11% to 13% from 9% to 12%.
“We are also raising total portfolio same-store NOI growth guidance to a range of 11% to 13%, up from 9% to 12%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $1.73M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at American Healthcare REIT
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
325 rated companies in Real Estate
- This company
- 55
- Sector median
- 55
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in REIT (Healthcare Facilities)
The next larger and next smaller companies by market value
- WelltowerWELL $179.68B59
- VentasVTR $47.41B47
- Omega Healthcare InvestorsOHI $14.31B66
- Healthpeak PropertiesDOC $13.87B53
- CareTrust REITCTRE $9.83B67
- Healthcare Realty TrustHR $6.65B46
- AedificaAED.BR $6.1B62
- Sabra Health Care REITSBRA $5.39B50
ETFs that hold American Healthcare REIT
Held by 18 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares US Property Yield UCITS ETFIQQ7 | 0.97% | 0.40% | €556.83M |
| State Street SPDR Dow Jones Global Real Estate UCITS ETF (Acc)SPY2 | 0.75% | 0.40% | €53.07M |
| VanEck Global Real Estate UCITS ETFTRET | 0.64% | 0.25% | €475.95M |
Show 5 more
| iShares Developed Markets Property Yield UCITS ETFIQQ6 | 0.62% | 0.59% | €813.1M |
| Amundi FTSE EPRA NAREIT Global UCITS ETF Dist10AJ | 0.53% | 0.24% | €606.07M |
| HSBC FTSE EPRA NAREIT Developed UCITS ETFH4ZL | 0.52% | 0.24% | €3.37B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.36% | 0.30% | €5.36B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.15% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Feb 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.